Nicolas Gower

Hematologue au CHU de Lille

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION

Ruth Flümann presents a multicenter retrospective analysis comparing CD20×CD3 bsAb-based bridging with glofitamab, epcoritamab, or glofitamab + GemOx (BisCAR; n = 67) vs conventional/no bridging (ConCAR; n = 45) before CAR T-cell therapy in patients with R/R LBCL (N = 112).

During bridging, Grade 3–4 cytopenia occurred in 3% of BisCAR vs 22% of evaluable ConCAR patients (n = 36). After CAR T-cell therapy, Grade 3–4 CRS occurred in 2% vs 7% and Grade 3–4 ICANS in 4% vs 13%, respectively. The ORR was 69% vs 61% during bridging and 80% vs 66% at Month 3 after CAR T-cell therapy; bridging strategy was not associated with inferior PFS or OS in multivariable analysis. Immune profiling suggested that bsAb-based bridging was compatible with effective CAR T-cell expansion and function.

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#lymphoma #lymsm #MedicalCongress @UKKoeln

[Eddie Cliff @Eddie_Cliff]

I felt the same - amongst the myeloma abstracts, there were many exciting BsAb studies, and the MajesTEC-4 data, tho preliminary, are incredibly exciting

@HadidiSamer

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #EHA2026 | PRESENTATION

Saad Usmani presents the final results from the phase III CEPHEUS study evaluating daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) vs VRd in TI-NDMM.
After a median follow-up of 76 months, D-VRd was associated with higher rates of MRD negativity than VRd, including 61.1% vs 40.0% at 10⁻⁵ (OR, 2,35; p = 0.0004) and 46.5% vs 27.6% at 10⁻⁶ (OR, 2.27; p = 0.001). D-VRd also reduced the risk of progression or death by 45% versus VRd (HR, 0.55; p = 0.0007). No additional safety concerns were identified with longer follow-up.

Follow our live feed for more updates: https://t.co/IjiLwPfcB5

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#MultipleMyeloma #myeloma #mmsm #MedEd

[Talha Badar @TalhaBadarMD]

📢 Late-Breaking Abstract #EHA2026

The phase 3 BRUIN CLL-322 trial demonstrated superior IRC-assessed PFS with fixed-duration pirtobrutinib + venetoclax + rituximab versus venetoclax + rituximab in previously treated CLL/SLL.

▪️ HR 0.547
▪️ 24-mo PFS: 86.9% vs 71.8%
▪️ Consistent benefit across high-risk subsets, including TP53 mutation/del(17p), unmutated IGHV, and complex karyotype
▪️ uMRD4: 86% vs 61%
▪️ Favorable safety profile

These data support PVR as a potential new standard-of-care option in relapsed/refractory CLL. #CLL #Hematology #EHA2026

[Ajay Major, MD, MBA @majorajay]

Do all older pts with MCL need 1L BR+BTKi? #lymsm
- 755 pts: all 1L BR
- mEFS after 1L BR 34 mo
- mEFS2 (1L BR➡️2L BTKi) 65 mo
- 5-yr OS 58%, 7-yr OS: 51%
- 76% received BTKi in 2L, mEFS after 2L BTKi 10 mos
- worse outcomes:⬆️sMIPI, Ki67 ≥50%, blastoid/pleomorphic, TP53mut, complex karyotype
Sequencing BR then BTKi appropriate in MCL, especially if no high-risk features. #lymsm
https://t.co/b0SEYUJWyl

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION

Arnon P. Kater presents interim results from HOVON 165/AETHER, evaluating fixed-duration venetoclax + epcoritamab in patients with R/R CLL/SLL under an amended protocol that added a third epcoritamab priming dose and mandated dexamethasone, antimicrobial prophylaxis, and CMV monitoring (safety-evaluable, n = 36).

At C9, the ORR was 100%, with CRi in 39% and PR in 61%; complete nodal responses were observed in 66% of patients. uMRD4 was reached early, with PB uMRD4 rates of 60% at C4 and 80% at C6 among patients with available PB MRD assessments (n = 30); in the paired C9 PB/BM subset (n = 20), uMRD4/5 was observed in 75% and 80%, respectively. After protocol amendment, CRS occurred in 55.6% (Grade ≥3, 2.8%), while no cases of ICANS or TLS were reported. Grade ≥3 neutrophil count decreased and infections occurred in 55.6% and 22.2%, respectively, with no Grade 4/5 AEs reported among events with ≥10% incidence.

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#lymphoma #lymsm #MedicalCongress @arnon_kater @amsterdamumc

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | POSTER
Kim Linton highlights results from an anchored match-adjusted indirect comparison of epcoritamab + R2 (EPCORE FL-1) vs tafasitamab + R2 (inMIND) in R/R FL.
Results suggest that epcoritamab + R2 is associated with higher response rates, improved PFS, and longer TTNT vs tafasitamab + R2 in R/R FL. These findings position epcoritamab + R2 as a potential new chemotherapy-free SoC in this patient population.
Follow our live feed for more updates: https://t.co/1YGTLomg50
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @TheChristieNHS

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION
Lei Fan, The First Affiliated Hospital of Nanjing Medical University, discusses results from an ongoing first-in-human phase I trial of LB2501, an in vivo CD19/CD20 dual targeting CAR T-cell therapy, in patients with R/R B-NHL (n = 12).
LB2501 has demonstrated a manageable safety profile, with no DLTs, SAEs, or ICANS, and encouraging initial efficacy at DL2, with an ORR and CR rate of 100% and 83.3%, respectively. While a longer-follow up is warranted, these findings support the continued development of LB2501 as a potential first-in-class, readily accessible off‑the‑shelf immunotherapy for patients with B‑cell malignancies.
Follow our live feed for more updates: https://t.co/1YGTLomg50
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress

[Toby Eyre @tobyeyre82]

▶️Primary results of BRUIN #CLL322 expertly presented by @DrMDavids as LBA PVR vs VR in RR CLL

2Y PFS 86.9% vs 71.8%

Esp. prominent benefit in
- cBTKi resistance
- TP53 mutation
- 1L cBTKi subgroups

Practice changing RCT
In press @TheLancet

#EHA2026 #Pirtobrutinib #PVR

[Graham Collins @graham74GC]

FrontMIND data interesting (Lenz et al)
• tafa-len-RCHOP v RCHOP IPI3-5 LBCL
• 3y PFS ⬆️ 6-7%
• higher in centrally r/v DLBCL
• no signif OS
• more tox: haem & GI
• no COO difference
• tafa weekly for all 6 cycles
Does benefit overcome tox & logistic impact.
#EHA2026

[Raul Cordoba, MD, PhD #EHA2026 @DrRaulCordoba]

JUST RELEASED 🚨 #Hematology Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell #lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial #lymsm https://t.co/JfIlfjt5i8

[Graham Collins @graham74GC]

Pembro + favezelimab vs chemo (gem or benda) in relapsed Classical Hodgkin. PFS primary endpoint met but development of fave ended by manufacturer. Quite a high CR rate on chemo control arm (?due to chemosensitisation or prior PD1i).

Close but no cigar….

#EHA2026

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | POSTER

@StefanoLuminari presents findings from a post-hoc analysis of the phase III inMIND study evaluating efficacy and safety outcomes in patients with R/R FL who received 1 prior line of therapy (2L cohort, N = 300; Tafa + Len + R, n = 147; PBO + Len + R, n = 153).
Median PFS by investigator was longer in the 2L cohort (24.0 vs 15.4 months; HR 0.40) and in 2L patients experiencing progression within 24 months of initiating 1L chemotherapy (POD24) (19.2 vs 11.7 months; HR 0.46) with Tafa vs placebo. ORR, CR rate, and TTNT were improved with Tafa vs placebo in both 2L and POD24 cohorts.
The safety profile in the 2L cohort was consistent with the overall study population.

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @UNIMORE_univ

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | POSTER

@KrishPatelMD discusses an exploratory analysis from a phase I/II study evaluating long-term outcomes of glofitamab in patients #LBCL who received 3 LOT and achieved a CR (N = 107).

Overall, 51.3%, 67.5%, and 51.5% of patients achieved a 5-year investigator-assessed median DOCR, OS, and PFS, respectively. The 5-year disease-specific OS was 86.0%, and PFS was 61.8%. Any grade AEs occurred in 98.1%, and Grade ≥3 AEs occurred in 63.6%. Additionally, immune recovery of B-cell, IgG, and IgM counts was observed.
Glofitamab shows durable remissions and OS with a manageable safety profile in patients with 3 LOT LBCL who achieved a CR.

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @SarahCannonDocs @SCRIOncology

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | POSTER

Pier Luigi Zinzani presents the preliminary findings from the phase I study evaluating the safety and efficacy of AZD3470, a PRMT5 inhibitor, in patients with R/R #cHL (N = 68).

Any grade TEAEs occurred in 91% of patients, while treatment-related AEs were reported in 69%. No DLTs, treatment discontinuations, or deaths were reported. The most common TEAEs included anemia (27%), fatigue (21%), and decreased appetite (15%). Grade ≥3 TEAEs occurred in 40% of patients, while SAEs were reported in 19%.

Among evaluable patients (n = 59), 44% of patients achieved ORR; the highest response rate was observed at a dose level of ≥450 mg (n = 31) with an ORR and CR rate of 58% and 35%, respectively.

Follow our live feed for more updates: https://t.co/SucPqSTSDg

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @Unibo

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION
Maria Bouzani, Evangelismos General Hospital, presents safety and 12-month efficacy results from a phase Ib study of golcadomide (Golca) + Pola-R-CHP in patients with newly diagnosed aggressive B-cell lymphoma (n = 57).
The safety profile was predictable, mainly hematologic, and did not compromise the delivery of chemotherapy (≥99% dose integrity). In the Golca 0.4 mg cohort, the EOT CMR was 89% and the 12-month PFS rate was 95.8%.
Golca 0.4 mg + R-CHOP is being evaluated in the ongoing phase III GOLSEEK-1 trial in high-risk 1L DLBCL.
Follow our live feed for more updates: https://t.co/1YGTLomg50
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION

Chan Y. Cheah, Sir Charles Gairdner Hospital, shares updated safety and efficacy data from the phase I/Ib BGB-11417-101 study evaluating first-line sonrotoclax + zanubrutinib in treatment-naive CLL/SLL, focusing on the 320 mg cohort (enrolled, N = 137; 320 mg cohort, n = 86; efficacy-evaluable, n = 84).

In the 320 mg cohort, the ORR was 100%, with CR in 59.5%; median TTR was 2.6 months. No PFS events occurred in the 320 mg cohort, with a 24-month PFS rate of 100%. Best blood uMRD4 rates by NGS increased from 81.2% at Week 24 to 91.8% at Week 48 and 98.2% at Week 96; the best uMRD5 rate was 87.3%, and uMRD4 rates were consistent regardless of mutation status. In the 320 mg cohort, Grade ≥3 TEAEs occurred in 60.5%, serious TEAEs in 31.4%, and TEAEs led to sonrotoclax discontinuation in 3.5%; no TLS or TEAE-related deaths occurred. The most common TEAEs were neutropenia (39%; Grade ≥3, 31%), contusion/bruising (38%), COVID-19 (33%; Grade ≥3, 2%), diarrhea (31%), and URTI (31%).

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#lymphoma #lymsm #MedicalCongress @chanyooncheah @uwanews @LinearClinical

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION

Matthew R. Wilson, Beatson West of Scotland Cancer Centre, Glasgow, presents findings from an international retrospective analysis evaluating HD-MTX for CNS relapse prophylaxis in patients with ultra high-risk LBCL receiving curative-intent chemoimmunotherapy (N = 1,923; HD-MTX, n = 872; no HD-MTX, n = 1,051).

HD-MTX did not significantly reduce 3-year CNS relapse vs no HD-MTX in UHR patients (6.6% vs 6.7%; adjusted HR, 0.95). Rates of isolated CNS relapse were also similar with HD-MTX vs no HD-MTX (4.8% vs 6.6%; adjusted HR, 0.81). In propensity score matching (501 pairs), 3-year CNS relapse was 7.4% vs 6.2% (HR, 0.86), and isolated CNS relapse was 5.3% vs 4.5% (HR, 0.83). No benefit was seen in any individual ultra high-risk subgroup. In the matched cohort, 3-year EFS and OS were similar with HD-MTX vs no HD-MTX (73.8% vs 73.7%; p = 0.65 and 82.6% vs 82.7%; p = 0.94).

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#lymphoma #lymsm #MedicalCongress @mattwilson2287

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION
Daniel Morillo presents long-term follow-up results from a phase I/II trial of golcadomide ± rituximab in patients with R/R FL (n = 60).
In efficacy-evaluable patients, ORR was 77% (CRR, 41%) at 0.2 mg, and 97% (CRR, 75%) at 0.4 mg. In the 0.4 mg group, responses were consistent in high-risk subsets, including patients with prior lenalidomide and/or T-cell–redirecting treatment. Golcadomide 0.4 mg + rituximab demonstrated high and durable responses with no new safety signals.
Follow our live feed for more updates: https://t.co/1YGTLomg50
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @Hospital_FJD

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION

Deok-Hwan Yang, Chonnam National University Hospital, shares results from VT-EBV-201, a randomized, double-blind phase II trial evaluating VT-EBV-N as post-remission therapy in patients with EBV+ extranodal NK/T-cell #lymphoma in CR (N = 46).

Patients were randomized 1:1 to receive VT-EBV-N (n = 21) or autologous PBMCs (control; n = 25). DFS was significantly improved with VT-EBV-N vs control (stratified log-rank p = 0.0210), with 2-year DFS of 95.0% vs 77.6% and 4-year DFS of 95.0% vs 56.3%, respectively. OS was 100% with VT-EBV-N at both 2 and 4 years vs 88.0% and 83.8% with control (p = 0.0205), with no deaths observed in the VT-EBV-N arm. Grade ≥3 AEs occurred in 10% vs 16%, with no Grade ≥3 or serious ADRs reported with VT-EBV-N.

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#lymsm #MedicalCongress @cnuh5102